KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.

Claude M Wischik, Richard Stefanacci, Peter Bentham, Serge Gauthier, Henrik Zetterberg, Gordon K Wilcock, Lutz Froelich, Alistair Burns, Emer MacSweeney, Clive Ballard, Jin-Tai Yu, Tay Siew Choon, Vahe Asvatourian, Natalia Muehlemann, Jan Priel, Karin Kook, Tenecia Sullivan, Diane Downie, Sonya Miller, Carol Pringle, John M D Storey, Tom Baddeley, Charles R Harrington, Lewis K Penny, Mohammad Arastoo, Roger Staff, Anca-Larisa Sandu, Helen Shiells, Serena Lo, Nafeesa Nazlee, Emily Evans, Claire Hull, Bjoern O Schelter

J Prev Alzheimers Dis 13(3) 100480

PMID41570392
PMCIDPMC12861207
DOI10.1016/j.tjpad.2026.100480
发表日期2026-01-22
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。
摘要

摘要

BACKGROUND: Hydromethylthionine mesylate (HMTM) targets tau pathology and has tau-independent symptomatic activity. OBJECTIVES: To evaluate the safety and efficacy of HMTM in participants with mild cognitive impairment (MCI) and mild to moderate dementia due to Alzheimer's disease (AD). SETTING: 82 centres in Canada, European Union, United Kingdom and United States of America. PARTICIPANTS: A total of 598 amyloid β-PET positive participants were included; 44% (263) met clinical criteria for MCI due to Alzheimer's disease and 56% (335) were diagnosed with mild to moderate dementia due to AD. INTERVENTION: HMTM 16 mg/day and 8 mg/day were compared with methylthioninium chloride (MTC) 4 mg twice weekly, intended as an inactive urinary colourant to preserve blinding with respect to possible urinary discolouration caused by HMTM. MEASUREMENTS: HMTM and MTC were compared on cognitive and functional endpoints for the first 52 weeks followed by all receiving HMTM 16 mg/day to 104 weeks in a modified delayed-start trial design. Biomarker outcomes included change in plasma levels of neurofilament light chain (NfL), pTau217 and MRI measures of grey matter atrophy. RESULTS: It was not possible to demonstrate significant differences on the co-primary clinical endpoints (ADAS-cog11 and ADCS-ADL23) at 52 weeks due to symptomatic activity in the control arm. In participants with MCI, statistically significant differences in cognitive decline (ADAS-cog13) emerged at 78 weeks (p = 0·0291) and 104 weeks (p = 0·0308) between early- and delayed-start HMTM 16 mg/day in analyses specified prior to the 24-month database lock. Statistically significant cognitive improvement over baseline score was sustained for 78 weeks in the early start MCI group, with no significant cognitive or functional decline to 104 weeks. There was a significant reduction in progression of neurodegeneration measured by NfL change (p = 0·0291) at 52 weeks in the whole population, consistent with significant reductions in progression of grey matter atrophy at 52 and 104 weeks, and a reduction in progression of tau pathology (pTau217, p = 0·0165) in MCI. Headache (1·5%) and diarrhoea (1·2%) were the most frequent adverse effects. CONCLUSIONS: Although HMTM 16 mg/day arrested progression of neurodegeneration and reduced grey matter atrophy at 52 weeks, symptomatic activity in the control arm precluded separation of treatment arms at 52 weeks on primary clinical endpoints. In participants with MCI, significant clinical separation was seen only at 78 and 104 weeks. This effect has been confirmed in a further study. HMTM was well tolerated and has the potential to offer an accessible oral treatment option with a benign safety profile which could be delivered with minimal patient/physician burden.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial profile. Abbreviations: DB=double-blind; D/ C =did not complete; ITT=intention to treat; OL=open label; tx=treatment.
非 KM Figure
Fig. 2Fig. 2 Cognitive, functional, and imaging endpoints. Prespecified efficacy results for the co-primary clinical, functional and secondary endpoints for all participants at 52-weeks: (A) ADAS-cog 11 (B) ADCS-ADL 23 and (C) whole brain volume (WBV). Corresponding outcomes in the MCI subgroup are shown at 104 weeks for: (D) ADAS-cog 13 , (E) ADCS-ADL 23 and (F) WBV. p-values indicate statistical significance of differences between arms as randomised. Asterisks indicate statistically significant improvement over baseline; * P < 0.05. Error bars denote SEM.
非 KM Figure
Fig. 3Fig. 3 Plasma biomarker outcomes. Change in plasma neurofilament light chain (NfL) concentration over 52-weeks in (A) whole population and (B) MCI subgroup. Change in pTau217 concentration over 104-weeks in (C) whole population (D) MCI subgroup. Error bars denote SEM.
非 KM Figure
Fig. 4Fig. 4 Statistical parametric mapping analysis comparing differences in change in GM volume over 52 and 104 weeks in subjects receiving HMTM (8mg/day or 16 mg/day) vs those receiving MTC 4 mg twice weekly. The locations of differences indicating statistically significant reduction in grey matter atrophy are shown in colour superimposed onto a normal control registered to a standardised template supplied with the SPM software platform ( www.fil.ion.ucl.ac.uk/spm/ ).
非 KM Figure
Fig. 5Fig. 5 Change from baseline in cognitive, functional, and imaging outcomes in MCI comparing MTC 4 mg twice weekly versus meta-analytic controls. (A) ADAS-Cog 13 , (B) ADCS-ADL 23 , and (C) whole-brain volume over 52 weeks in participants with MCI treated with MTC 4 mg twice weekly compared with meta-analytic control data. Error bars represent the standard error of the mean (SEM).
非 KM Figure